-
-
-
-
-
-
-
aTyr Pharma schedules FDA meeting for efzofitimod drug program
-
-
-
-
-
-
-
H.C. Wainwright Downgrades aTyr Pharma (ATYR) to Neutral
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on aTyr Pharma (ATYR)
-
-
-
-
-
-
-
aTyr Pharma (ATYR) Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on aTyr Pharma (ATYR)
-
-
-
-
-
-
-
aTyr Pharma (ATYR) Appoints Eric Benevich to its Board
-
-
-
-
-
-
-
aTyr Pharma's (ATYR) Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
-
479,046 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


